MediGene AG has appointed Dolores Schendel as chief scientific officer. Former Director of the Institute of Molecular Immunology at the Helmholtz-Zentrum Munchen and Managing Director of Trianta Immunotherapies GmbH, Prof. Schendel will now be the Executive Board member responsible for R&D at Medigene. She will continue as Member of the Management Board of Trianta Immunotherapies GmbH, which was acquired by Medigene in January 2014.
Market Closed -
Other stock markets
|
After market 17:03:42 | |||
1.18 EUR | +2.16% |
|
1.168 | -1.02% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.62% | 36.79M | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene Appoints Dolores Schendel as Chief Scientific Officer